A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
ConditionNon-Small Cell Lung Cancer
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorVerastem, Inc.
About this trial
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Non-Small Cell Lung Cancer
Eligibility criteria
Qualifiers
Histopathology confirmed unresectable locally advanced or metastatic NSCLC
Measurable disease per RECIST 1.1
Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)
ECOG PS=0 or 1
Disqualifiers
Have any other documented co-existing common RAS mutation(s)
Prior anti-cancer Tx within 4 weeks or drug-specific timeline within first treatment dose, whichever shorter
Major surgery within 4 weeks of first treatment dose
Radiation therapy (RT) within 1 week of first treatment dose
Trial design
Treatments tested in this trial
- VS-7375
Treatment groups
105 Participants
are divided into 3 treatment groupsLocations
3START LA90025, Los AngelesCalifornia, United States
START New Jersey08816, East BrunswickNew Jersey, United States
START Fort Worth76104, Fort WorthTexas, United States
Sponsors and collaborators
Verastem, Inc.
Lead sponsor
Source ClinicalTrials.gov